Revenue Comparison
Chart: Revenue Comparison. Values in USD_BILLIONS. In Q2 2026: Gilead Sciences 7.803, Becton Dickinson 4.983.
Gilead Sciences vs Becton Dickinson Net Worth and Market Cap
Gilead Sciences (GILD) and Becton Dickinson (BDX) are peers in Healthcare. Gilead Sciences reported revenue of $7.8B as of Q2 2026, compared with $5.0B for Becton Dickinson. Gilead Sciences leads on revenue.
Gilead Sciences's gross margin is 79.8% versus 46.5% for Becton Dickinson. Gilead Sciences's net margin is -134.5% versus 7.6% for Becton Dickinson.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Gilead Sciences, Becton Dickinson.| Metric | Gilead Sciences | Becton Dickinson |
|---|---|---|
| Market Cap | - | - |
| Revenue | $7.80B | $4.98B |
| Cost of Revenue | $1.58B | $2.67B |
| Gross Profit | $6.22B | $2.31B |
| Operating Income | $-10.39B | $663.00M |
| Net Income | $-10.50B | $377.00M |
| R&D Expense | $1.76B | $258.00M |
| Earnings Per Share | -$8.45 | $1.37 |
| Gross Margin | 79.8% | 46.5% |
| Operating Margin | -133.2% | 13.3% |
| Net Profit Margin | -134.5% | 7.6% |
| Free Cash Flow | $3.69B | $509.00M |
| Cumulative Free Cash Flow | $155.83B | $39.60B |
| Operating Cash Flow | $3.57B | $652.00M |
| Cash & Equivalents | $3.18B | $708.00M |